Body Composition Monitor in Hemodialysis Patients
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Control of volume status is a pivotal issue in haemodialysis therapy. Objective and practical management for maintaining normovolemia is needed.
The investigators hypothesized that intervention of volume status with the body composition monitor (BCM) may improved hemodynamic parameters and biomarkers in hemodialysis patients.
| Condition | Intervention | Phase |
|---|---|---|
|
End Stage Renal Disease |
Behavioral: control of ultrafiltration |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | The Association Between Body Composition and Biomarkers in Hemodialysis Patients |
- blood pressure [ Time Frame: up to 16 weeks ] [ Designated as safety issue: Yes ]Systolic blood pressure, number of anti-hypertensive agents hypotensive episode
- biomarkers [ Time Frame: up to 16 weeks ] [ Designated as safety issue: Yes ]C-reactive protein, interleukin-6, MMP-1, leptin, resistin, adiponectin, VEGF
| Estimated Enrollment: | 160 |
| Study Start Date: | April 2010 |
| Estimated Study Completion Date: | December 2010 |
| Estimated Primary Completion Date: | October 2010 (Final data collection date for primary outcome measure) |
-
Behavioral: control of ultrafiltration
The investigators will assess BCM in enrolled hemodialysis patients by 4 weeks for 16 weeks During the former 8-week intervention period, The investigators will adjust patients' volume status according to the results of BCM.
During the latter 8-week observational period, The investigators will evaluate the changes of patients' hemodynamic parameters and biomarkers.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 6-month or more stable hemodialysis patients
- 18 years or more
- less than 5% of changes of dry weight for last 3 months
Exclusion Criteria:
- pregnancy
- active malignancy
- cardiac pacemaker or defibrillator
- history of extremity amputation
- active infectious disease within 3 months
- admission history for complication related to hemodialysis within 3 months
Contacts and Locations| Contact: Sejoong Kim, MD, PhD | 82-32-460-8305 | imsejoong@hanmail.net |
| Contact: Kwon Wook Joo, MD, PhD | 82-2-2072-1964 | junephro@paran.com |
| Korea, Republic of | |
| Sejoong Kim | Recruiting |
| Incheon, Korea, Republic of, 405-760 | |
| Contact: Sejoong Kim, MD, PhD 82-32-460-8305 imsejoong@hanmail.net | |
| Contact: Kwon Wook Joo, MD, PhD 82-2-2072-1964 junephro@paran.com | |
| Sub-Investigator: Kwon Wook Joo, MD, PhD | |
| Sub-Investigator: Ho Jun Chin, MD, PhD | |
| Principal Investigator: | Sejoong Kim, MD, PhD | Gachon University Gil Medical Center |
More Information
No publications provided
| Responsible Party: | Gachon University Gil Medical Center IRB, Gachon University Gil Medical Center |
| ClinicalTrials.gov Identifier: | NCT01103167 History of Changes |
| Other Study ID Numbers: | korea_bcm_hd |
| Study First Received: | April 9, 2010 |
| Last Updated: | April 13, 2010 |
| Health Authority: | Korea: Institutional Review Board |
Keywords provided by Gachon University Gil Medical Center:
|
body composition blood pressure hemodialysis |
Additional relevant MeSH terms:
|
Kidney Diseases Kidney Failure, Chronic Urologic Diseases Renal Insufficiency, Chronic Renal Insufficiency |
ClinicalTrials.gov processed this record on May 16, 2013